在衰老,新陈代谢和神经退行过程中的NAD+
1Gladstone Institutes, Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA.
概括
尼古丁胺氨基二核酸 (NAD) 的水平随着年龄的增长而下降. 补充NAD(+) 前体可能为衰老和神经退行性疾病提供治疗益处.
科学领域:
- 生物化学
- 细胞生物学
- 老龄化研究
背景情况:
- 尼古丁胺氨基二核酸 (NAD(+)) 是所有活细胞中的重要辅酶.
- 它参与氧化还原反应,并作为素等酶的辅基质.
- 随着年龄的增长,细胞中的NAD () 水平下降,影响健康和寿命.
研究的目的:
- 审查调节NAD) 代谢的因素.
- 讨论NAD ((+) 前体对衰老和相关疾病的治疗潜力.
- 探索用于神经退行性疾病的NAD(+) 前体补充剂.
主要方法:
- 关于NAD(+) 代谢的文献评论.
- 分析有关NAD的调节研究.
- 对NAD ((+) 前体和衰老的研究的回顾.
主要成果:
- NAD ((+) 在细胞能量和信号传递中起着至关重要的作用.
- 与年龄相关的NAD下降与健康和寿命的减少有关.
- 在调节衰老过程中,NAD ((+) 前体显示出有前途.
结论:
- 对于抗衰老的干预措施来说,NAD () 代谢是关键的目标.
- 补充NAD ((+) 前体可能提供一种新的治疗策略.
- 对于与年龄相关的疾病,特别是神经退行症的NAD(+) 前体疗效,需要进一步研究.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
2.0K
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
3.1K
相关概念视频
Aging
983
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
983
Mitochondria
21.3K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.3K
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
818
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
818
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Pharmacodynamics in Geriatric Patients: Effects of Age
315
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
315
